Prostate-specific antigen responses were similar between transdermal estradiol and hormone therapy combined with androgen ...

Prostate cancer cells usually require male androgen hormones, such as testosterone, to grow. Androgen deprivation therapy ...

Responses were similar among patients with estrogen patches and ARPIs compared to luteinizing hormone releasing hormone ...

Savita Dandapani, MD, PhD, discusses the rationale behind a study evaluating the combination of radium-223, hormone therapy, ...

Investigators report that estradiol works as well as luteinizing hormone–releasing hormone agonists for testosterone suppression and have a much better side-effect profile.

Quality of life, treatment impact and duration, and the importance of individualized therapy are at the center of ...

A major discovery by Australian researchers of a key driver of prostate cancer could lead to the next generation of targeted ...

New Data for NUBEQA® Build on Safety and Efficacy Results Across Subgroups of Patients with Metastatic Hormone-Sensitive ...

Untreated prostate cancer can sometimes cause erectile dysfunction (ED). However, ED is more commonly associated with ...

Data will include a subgroup analysis from the investigational Phase III ARANOTE trial, evaluating the efficacy and safety of NUBEQA ® (darolutamide) and androgen-deprivation therapy (ADT) in patients ...

Dr. Barry W. Goy explains how to interpret PSA levels after prostate cancer treatment and how to manage recurrence based on ...